Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease

Robert N. Schuck, Janet Woodcock, Issam Zineh, Peter Stein, Jonathan Jarow, Robert Temple, Thomas Permutt, Lisa LaVange, Julia A. Beaver, Rosane Charlab, Gideon M. Blumenthal, Sarah E. Dorff, Christopher Leptak, Steven Lemery, Hobart Rogers, Badrul Chowdhury, E. David Litwack, Michael Pacanowski

Research output: Contribution to journalArticlepeer-review

Abstract

Advances in our understanding of the molecular underpinnings of disease have spurred the development of targeted therapies and the use of precision medicine approaches in patient care. While targeted therapies have improved our capability to provide effective treatments to patients, they also present additional challenges to drug development and benefit–risk assessment such as identifying the subset(s) of patients likely to respond to the drug, assessing heterogeneity in response across molecular subsets of a disease, and developing diagnostic tests to identify patients for treatment. These challenges are particularly difficult to address when targeted therapies are developed to treat diseases with multiple molecular subtypes that occur at low frequencies. To help address these challenges, the US Food and Drug Administration recently published a draft guidance entitled “Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.” Here we provide additional information on specific aspects of targeted therapy development in diseases with low-frequency molecular subsets.

Original languageEnglish (US)
Pages (from-to)282-289
Number of pages8
JournalClinical pharmacology and therapeutics
Volume104
Issue number2
DOIs
StatePublished - Aug 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease'. Together they form a unique fingerprint.

Cite this